Pharmaceuticals

Insilico Medicine's AI-designed drug, ISM8969, enters human trials, targeting chronic neuroinflammation by crossing the elusive blood-brain barrier.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

At BIO 2026, Israeli biotech Can-Fite seeks crucial partnerships for its late-stage cancer and inflammation drugs, built on a unique, safety-focused platform.

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

Choosing the wrong regulatory partner can derail a market launch. A new guide from Q&C Services offers a veteran's roadmap for de-risking expansion.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.

A new survey reveals the deep toll of canine skin allergies on pets and owners, exposing a massive unmet need that has pharmaceutical giants racing for a cure.

ARMR Sciences reports a major breakthrough in the fight against overdose, but can a preventative vaccine truly turn the tide on the fentanyl crisis?

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

A Swedish pharma company's trial is progressing faster than expected, but the real story is the potential paradigm shift for millions suffering from a neglected disease.

A new AU$481M deal with Everest Medicines brings a promising FSGS drug closer to 1M Asian patients, part of a larger, de-risked global strategy.

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

Assertio Holdings delists from Nasdaq after its merger with Zydus. A deep dive into the strategic calculus and the crucial decision facing its debt holders.

Biotech firm Azitra is leveraging its engineered microbe tech to tackle rare diseases and enter the $71B cosmeceutical market. Is this a brilliant pivot or a risky bet?

New appointments bring deep legal and pharma expertise to Canada's Patented Medicine Prices Review Board, signaling a pivotal moment under new 2026 guidelines.

A new bill named for a man failed by the system aims to modernize medical psilocybin access. But can it overcome bureaucratic inertia and position Canada as a leader?